Alexia Moutsatsos, MD
Internal Medicine · Elkton, MDNPI 1811024631
Payments from drug & device makers
Across 466 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$887
- Novo Nordisk$815
- AbbVie$756
- Lilly USA, LLC$598
- Amgen$590
- plus $4K from 33 others
What the payments were for
- Food & beverage$8,260100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 56 | $1,044 |
| GSK | 62 | $887 |
| Novo Nordisk | 43 | $815 |
| AbbVie | 38 | $756 |
| Lilly USA, LLC | 38 | $598 |
| Amgen | 35 | $590 |
| Astellas Pharma US Inc | 36 | $536 |
| Pfizer | 25 | $440 |
| Boehringer Ingelheim | 21 | $312 |
| Abbott | 12 | $226 |
| Sanofi-aventis U.S. LLC | 8 | $196 |
| Otsuka America Pharmaceutical, Inc. | 4 | $177 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $155 |
| Merck | 9 | $142 |
| Johnson & Johnson | 7 | $137 |
| Gilead | 6 | $136 |
| Amarin Pharma, Inc. | 4 | $120 |
| Medtronic | 3 | $112 |
| Sanofi Pasteur Inc. | 6 | $107 |
| Teva Pharmaceuticals USA, Inc. | 6 | $97 |
| VBI Vaccine (delaware) Inc. | 3 | $74 |
| Bayer | 3 | $71 |
| Currax Pharmaceuticals LLC | 4 | $55 |
| Exact Sciences | 3 | $53 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Nalpropion Pharmaceuticals LLC | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Valeritas, Inc. | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $23 |
| Eisai Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $22 |
| Soleno Therapeutics, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $17 |
| Novartis | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$8,274 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 119 | $166,129 |
| JardianceEmpagliflozin | 111 | $95,497 |
| MounjaroTirzepatide | 70 | $90,742 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $73,735 |
| EliquisApixaban | 98 | $72,471 |
| CreonLipase/Protease/Amylase | 23 | $60,810 |
| XareltoRivaroxaban | 161 | $59,610 |
| TrulicityDulaglutide | 27 | $38,218 |
| XifaxanRifaximin | 43 | $24,752 |
| FarxigaDapagliflozin Propanediol | 14 | $22,501 |
| MyrbetriqMirabegron | 21 | $19,864 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $8,738 |
| Colesevelam Hcl | 14 | $8,676 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $8,443 |
| TradjentaLinagliptin | 27 | $6,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $815 | $166,129119 claims |
| Lilly USA, LLCMounjaro, Trulicity | $598 | $128,96097 claims |
| Boehringer IngelheimJardiance, Tradjenta | $312 | $102,489138 claims |
| GSKTrelegy Ellipta | $887 | $73,73555 claims |
| PfizerEliquis | $440 | $72,47198 claims |
| AbbVieCreon, Synthroid | $756 | $64,71761 claims |
| Johnson & JohnsonXarelto | $137 | $59,610161 claims |
| AstraZenecaFarxiga, Symbicort | $1,044 | $28,25925 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $155 | $24,75243 claims |
| Astellas Pharma US IncMyrbetriq | $536 | $19,86421 claims |
| MerckJanumet Xr | $142 | $8,73818 claims |
| Sanofi-aventis U.S. LLCRenvela | $196 | $3,42412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Elkton
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.